I’ve been trying to keep on top of articles relating to rapid review methods and the long list can be found here. After significant growth in papers over the last 8-10 years there was, last year, a drop-off in methods papers (that I could find). This year has been marginally better, but still not loads. Here are the ones for this year: To HTA … Continue reading Rapid review articles, so far, in 2019
Abstract Evidence synthesis is a key element of evidence-based medicine. However, it is currently hampered by being labour intensive meaning that many trials are not incorporated into robust evidence syntheses and that many are out of date. To overcome this, a variety of techniques are being explored, including using automation technology. Here, we describe a fully automated evidence synthesis system for intervention studies, one that … Continue reading Developing a fully automated evidence synthesis tool for identifying, assessing and collating the evidence
Rapid network meta-analysis using data from Food and Drug Administration approval packages is feasible but with limitations J Clin Epidemiol. Wang L et al. Great to see this abstract! Without the abstract I’m not sure how rapid ‘rapid’ actually is. Also, it’s unclear how close the results were, aside from the very nice ‘tease’ of: “Compared to an NMA including all unique trials, we … Continue reading Rapid network meta-analysis using data from Food and Drug Administration approval packages is feasible but with limitations
Last week I posted An interesting exchange on Twitter. In that I ended with this: When might: the largest trial suffice? when might a rapid review suffice? when might a systematic review suffice? when might you need to do a full systematic review, using all the data (including unpublished data including CSRs as seen with the Tamiflu work of Tom Jefferson)? This triggered further exchanges … Continue reading An interesting exchange on Twitter – reflections
Last week I presented at the JBI European Symposium in Cardiff, one part of the discussion related to rapid reviews. Following that a Twitter conversation started: There were other messages in the exchanges but you get the picture! A few observations: I’m still unsure if James believes we need all the data or not when doing an evidence synthesis. Assuming we don’t need all the … Continue reading An interesting exchange on Twitter
Challenges of rapid reviews for diagnostic test accuracy questions: a protocol for an international survey and expert consultation Diagnostic and Prognostic Research 2019 3:7. Arevalo-Rodriguez I et al The journal is not in PubMed so easily missed…: Assessment of diagnostic tests, broadly defined as any element that aids in the collection of additional information for further clarification of a patient’s health status, has increasingly … Continue reading Challenges of rapid reviews for diagnostic test accuracy questions: a protocol
The Impact of Study Size on Meta-analyses: Examination of Underpowered Studies in Cochrane Reviews Turner RM, Bird SM, Higgins JP. PLoS One. 2013;8(3):e59202. An old paper but one someone pointed out recently and it’s one that mentions rapid reviews in a number of places, notably: “When at least two adequately powered studies are available in meta-analyses reported by Cochrane reviews, underpowered studies often contribute little … Continue reading The Impact of Study Size on Meta-analyses: Examination of Underpowered Studies in Cochrane Reviews
Shame this is behind a paywall as it looks really interesting! Objectives Reimbursement systems are evolving and endeavor to balance access and affordability. One such evolution in Ireland is the compulsory rapid review (RR) process, the outcome from which is a recommendation for a health technology assessment (HTA) or no HTA. For drugs that avoid an HTA, evaluation times are shorter, lengthy price negotiations … Continue reading To HTA or Not to HTA: Identifying the Factors Influencing the Rapid Review Outcome in Ireland
As part of updating the Trip Database I noticed the AHRQ have a new category ‘Rapid Evidence Product’ which currently has two entries: Patient Navigation Models for Lung Cancer (Dec 2018) Addressing Social Isolation To Improve the Health of Older Adults: A Rapid Review (Feb 2019) To whet your appetite this is how the method appears in the abstract of the latter review: Methods. We … Continue reading AHRQ dipping their toe in to the ‘rapid’ world
I spotted this news via the BMJ and I wanted to share as these (CSRs) are an important component of the debate around rapid versus systematic reviews. I have long argued that terms such as ‘rapid’ and ‘systematic’ are mis-leading and the CSR helps illustrate this point. Rapid – is a relative term and open to interpretation. I would see rapid as taking a day … Continue reading FDA to begin releasing clinical study reports in pilot programme
Rapid-Reviews.info 